The Lung Cancer Initiative of North Carolina is pleased to announce that Boehringer Ingelhiem has signed on as a Platinum Corporate Sponsor. Our corporate sponsors are committed to helping us sustain and grow our lung cancer education, awareness and fundraising efforts throughout the year.
Since 2008 the Lung Cancer Initiative of North Carolina has funded close to a million dollars in lung cancer research. In 2015 we will fund lung cancer research fellows from four institutions across the state. The Lung Cancer Initiative also has programs to help educate the public and local health care providers as well as the Access to Care Gas Card Program, which provides assistance to lung cancer patients who are seeking treatment, including clinical trials; the goal of the program is to lessen the financial burden for patients to receive appropriate lung cancer treatment.
Amy Cipau, President of the Lung Cancer Initiative, commented “Boehringer Ingelheim’s Platinum Sponsorship is a solid commitment to the Initiative’s mission, as well as lung cancer patients and their families. This level of support provides for the Initiative’s major events, as well as our advocacy summit, newsletters and Expert Speaker Series. We are actively seeking additional partnerships such as these.” For more information please contact Heather Hooper, Executive Director at HHooper@LungCancerInitaitiveNC.org or call 919-784-0410.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies, and commercializes Afatinib (GIOTRIF® / GILOTRIFTM) which is indicated for specific forms of treatment of EGFR mutation positive locally advanced or metastatic non-small cell lung cancer.